Alligator Bioscience AB (publ) reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported sales was SEK 11.74 million compared to SEK 20.06 million a year ago. Revenue was SEK 12.91 million compared to SEK 20.91 million a year ago. Net loss was SEK 69.83 million compared to SEK 53.25 million a year ago. Basic loss per share from continuing operations was SEK 0.11 compared to SEK 0.24 a year ago. Diluted loss per share from continuing operations was SEK 0.11 compared to SEK 0.24 a year ago.
For the full year, sales was SEK 58.11 million compared to SEK 35.7 million a year ago. Revenue was SEK 61.9 million compared to SEK 37.14 million a year ago. Net loss was SEK 248.59 million compared to SEK 193.4 million a year ago. Basic loss per share from continuing operations was SEK 0.55 compared to SEK 0.88 a year ago. Diluted loss per share from continuing operations was SEK 0.55 compared to SEK 0.88 a year ago.